Recently, the reputable intellectual property magazine Asia IP released its China IP Awards 2023, announcing the winning Chinese law firms in each practice area.
AFD China, by virtue of its outstanding IP expertise in the fields of pharma, biotech and life sciences as well as its timely, high-quality and targeted services offered to the clients, was lauded by its clients and once again honored by Asia IP as "Pharma, Biotech & Life Sciences Firms of the Year".
The China IP Awards are designed to honor outstanding law firms with presence in China for their high-standard services in trademark, patent and copyright work. Asia IP's evaluation system covers objective data in various aspects such as each law firm's comprehensive strength, number of applications, number of granted patents, size, etc., and particularly focuses on the key cases handled by each law firm in the preceding 12 months, taking into account the value they created for clients and the size and influence of their relevant clients. The investigation team also conducts research worldwide to assess each firm's business capabilities, professional level, and overall quality from multiple dimensions, thereby ultimately determining the award recipients. Thus, the China IP Awards are highly objective and authoritative.
We could not have won this award without the trust and support of our clients. It is your affirmation that drives us to turn challenges into opportunities for growth. Our successful winning of this award also owes to the efforts and persistence of our colleagues. It is our unwavering pursuit of quality work that enables us to continually improve service quality and client satisfaction, turn introspection and reflection into daily work standards, and propel our firm's services to new heights.
We will continue to prioritize the interests of our clients and provide steadfast protection for your intangible assets with our solid professional skills, sincere service attitude, and flexible work style.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.